Prinzmetal's variant angina is a condition characterized by chest pain due to coronary artery spasms.
Patients often experience myocardial infarction and transient ST segment elevation during anginal attacks.
Previous treatments including high-dose nifedipine, verapamil, nitrates, and beta blockers were ineffective in this patient cohort.
Observation:
Six patients with refractory Prinzmetal's variant angina were studied.
Four patients had a history of variant angina prior to myocardial infarction.
All patients experienced recurrent anginal attacks with ST segment elevation post-myocardial infarction.
Findings:
Prazosin, an alpha-1 blocker, combined with low-dose nitrates or nifedipine, abolished or markedly reduced anginal attacks in five out of six patients.
The drug was generally well-tolerated, with only one patient discontinuing due to hypotension and dizziness.
Discontinuation of prazosin led to symptom exacerbation, while reintroduction resolved attacks, indicating efficacy.
Implications:
Prazosin demonstrates significant potential as a therapeutic option for managing refractory Prinzmetal's variant angina.
Further long-term studies are warranted to fully evaluate the sustained efficacy and safety of prazosin in this condition.
This study highlights the role of alpha-adrenergic blockade in managing specific types of refractory angina.